Gland Pharma Share Price Surges 16% on Blockbuster Q4 Results

Gland Pharma Share Price Surges 16%: Stock Hits New 52-Week High on Stellar Q4 Performance and 97% Profit Jump

Mumbai, May 18, 2026 – Shareholders of Gland Pharma witnessed a historic trading session on Monday as the pharmaceutical major’s stock price skyrocketed following a blockbuster earnings report for the final quarter of the fiscal year 2025-26 (Q4FY26).

Driven by an astonishing 97% year-on-year (YoY) surge in consolidated net profit and robust growth across its core segments, the stock established fresh milestones on the bourses, cementing its position as one of the top performers in the pharmaceutical sector this quarter.

Market Reaction: Gland Pharma Stocks Touch the Sky

The market opened to an overwhelmingly bullish sentiment for Gland Pharma, with intense buying pressure driving the stock up by as much as 18% from its previous closing price during intraday trading. The stock touched an impressive 52-week high of ₹2,205.00 on the Bombay Stock Exchange (BSE).

While some late-day profit booking softened the initial peak, the stock maintained its powerful momentum, eventually settling at ₹2,159.20 per share, representing a massive single-day gain of 15.6%. This explosive rally pushed the company’s total market capitalization past the coveted ₹35,500 crore threshold, reflecting renewed investor confidence in the company’s long-term growth trajectory.

Over the past 12 months, Gland Pharma has delivered an impressive 47% return to its investors, significantly outperforming broader defensive indices.

Q4 FY2025-26 Financial Performance: A Deep Dive

The financial results for the January-March 2026 quarter, released post-market hours on Friday, May 15th, acted as the primary catalyst for Monday’s massive re-rating. Gland Pharma reported across-the-board beats on revenue, operational margins, and profitability.

Net Profit and Revenue Breakdown

• Consolidated Net Profit: The company’s net profit nearly doubled, posting a staggering 97% YoY growth to ₹366.7 crore, up from ₹186.5 crore in the corresponding quarter of the previous fiscal year (Q4FY25).

• Revenue from Operations: Top-line revenue witnessed a robust expansion of 22% YoY, reaching ₹1,742.8 crore compared to ₹1,424.9 crore in the March 2025 quarter.

Operational Efficiency & Margin Expansion

Gland Pharma’s operating metrics showcased exceptional resilience and pricing power:

• EBITDA Growth: Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter spiked by nearly 48% YoY.

• EBITDA Margins: Driven by favorable product mix, improved capacity utilization, and operational efficiencies, the EBITDA margin expanded aggressively to 29%, a significant step up from previous quarters.

The Engine of Growth: CDMO Segment Leads the Charge

A deeper look into the revenue streams reveals that Gland Pharma’s core strength lies in its Contract Development and Manufacturing Organization (CDMO) business. The company has successfully leveraged its specialized capabilities in injectables and complex generics to secure high-value global contracts.

During the March 2026 quarter, the CDMO segment:

• Contributed an impressive 46% to the total consolidated revenue.

• Registered a formidable 36% YoY growth rate, outperforming the company’s baseline growth.

By positioning itself as a reliable, high-quality partner for global innovators and generic players alike, Gland Pharma has effectively insulated itself from the severe price erosion that has plagued standard oral-solid generic businesses globally.

Full-Year FY2025-26 Round-Up and Future Guidance

The stellar fourth quarter capped off a highly successful full fiscal year (FY26) for Gland Pharma, showcasing consistent operational execution over the 12-month period.

FY26 Consolidated Full-Year Financial Highlights

• Total Revenue from Operations: ₹6,430.65 crore

• Consolidated Net Profit: ₹1,027.31 crore

• Adjusted EBITDA Growth: Increased by 33% YoY

• Full-Year EBITDA Margin: Stood strong at 26%

• Full-Year CDMO Contribution: Maintained a steady 46% share of total annual sales.

Management Outlook for FY2027 and Beyond

Looking ahead, Gland Pharma’s management has maintained a confident yet measured outlook for the upcoming fiscal years. For FY2027, the management expects a top-line growth of 12% to 13%. This growth is expected to accelerate in the subsequent years as newly commissioned capacities scale up and several complex injectable filings receive regulatory approvals in regulated markets like the United States and Europe.

Analyst Radar: Buy, Sell, or Hold?

The stellar performance triggered an immediate wave of upgrades from prominent institutional brokerages, shifting market sentiment from cautious optimism to outright bullishness.

Kotak Institutional Equities Upgrades Stock

In a notable revision, Kotak Institutional Equities upgraded its rating on Gland Pharma from “Reduce” straight to “Add.” Concurrently, the brokerage aggressively raised its target price from ₹1,770 to ₹2,075 per share.

Remarkably, the stock’s massive 16% single-day surge on Monday blew right past this revised target price, indicating that the market may be pricing in an even faster recovery than institutional models initially projected.

Long-Term Growth Forecasts (FY26–FY29)

Kotak’s updated investment thesis is anchored on steady accelerating growth and powerful operating leverage over the next four years:

• FY2027 Projected Growth: 12–13%

• FY2028 Projected Growth: 15%

• FY2029+ Projected Growth: 19–20%

• Consolidated 4-Year CAGR: Estimated at a healthy 15%.

• Earnings Per Share (EPS) CAGR: Projected at a powerful 22% over FY26–29, driven extensively by a pipeline of new product launches and optimizing underutilized manufacturing lines.

Consensus Analyst Sentiment

The broader analyst community remains overwhelmingly positive on the counter. Out of 18 analysts actively tracking Gland Pharma:

• 13 Analysts recommend a “Buy” or strong buy.

• 2 Analysts maintain a “Hold” rating.

• 3 Analysts retain a “Sell” rating.

Shareholders Reward: Gland Pharma Announces ₹20 Dividend

To share the rewards of this highly profitable fiscal year directly with its retail and institutional backers, the Board of Directors has proposed a lucrative dividend payout.

Gland Pharma is planning to declare a final dividend of ₹20 per share for the fiscal year 2025-26.

Key Dividend Dates to Remember:

• Record Date: August 11, 2026. Investors who hold the stock in their demat accounts prior to or on this date will be legally entitled to the payout.

• Approval Date: The dividend will be put forward for formal approval by the shareholders at the upcoming Annual General Meeting (AGM) scheduled for August 25, 2026.

• Payout Timeline: Upon receiving the formal nod at the AGM, the dividend distribution will be executed and credited directly to eligible shareholders’ bank accounts within 30 days.

The Road Ahead

Gland Pharma’s spectacular Q4 turnaround proves that its B2B model and injectables focus remain fundamentally sound. While the stock has quickly outrun some immediate brokerage targets, the projected 22% EPS compound annual growth rate over the next three years suggests that for long-term investors, this pharma heavy-hitter still has plenty of runway left to explore.